Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.50 |
| ▸ | GBA1 | P04062 | 6/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11214480 | 0.91 | GNAI3 (0.47) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL11302086 | 0.76 | GNAI3 (0.53) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL7042804 | 0.74 | GNAI3 (0.56) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL7041937 | 0.74 | GNAI3 (0.56) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL7043466 | 0.73 | GNAI3 (0.50) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL11667780 | 0.71 | GNAI3 (0.38) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL10906234 | 0.71 | PRCP (0.49) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL6401701 | 0.70 | GNAI3 (0.51) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL10945126 | 0.70 | GNAI3 (0.51) | GNAI3GNAO1GNAI1GBA1PRCP | |
| SCHEMBL3265058 | 0.70 | GNAI3 (0.92) | GNAI3GNAO1GNAI1GBA1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-2007705-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080300292-A1 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders | NITROMED, INC (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2006102071-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006093864-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006078995-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING HETEROCYCLIC NITRIC OXIDE DONOR GROUP COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006052899-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISORDERS | NITROMED, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-4396617-A | FUNGICIDES | DUPHAR INTERNATIONAL B.V. (NL) | 1983-08-02 | — | — | US | disclosed |
| US-4374143-A | AS FUNGICIDES | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1983-02-15 | — | — | US | disclosed |
| EP-0007438-B1 | SUBSTITUTED 2-PHENYLAMINO-2-IMIDAZOLINES, THEIR ACID ADDITION SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1982-09-01 | — | — | EP | disclosed |
| EP-0001663-B1 | NOVEL 2-ARYLAMINO-HEXAHYDROPYRIMIDINES AND -IMIDAZOLIDINES, SALTS AND COMPLEXES THEREOF, METHOD OF PREPARING THE NOVEL COMPOUNDS AND FUNGICIDAL COMPOSITIONS WHICH CONTAIN THE NOVEL COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1982-05-12 | — | — | EP | disclosed |
| EP-0001663-A1 | Novel 2-arylamino-hexahydropyrimidines and -imidazolidines, salts and complexes thereof, method of preparing the novel compounds and fungicidal compositions which contain the novel compounds | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | GNAI3 2450/4885GNAO1 805/4885GNAI1 2560/4885 |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | GNAI3 1027/4885GNAO1 294/4885GNAI1 737/4885 |
| US-20080300292-A1 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders | NOS3, NOS1, NOS2 | GNAI3 345/4885GNAO1 201/4885GNAI1 405/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | GNAI3 1642/4885GNAO1 418/4885GNAI1 1476/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | GNAI3 1406/4885GNAO1 399/4885GNAI1 1516/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | GNAI3 721/4885GNAO1 173/4885GNAI1 560/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | GNAI3 2417/4885GNAO1 1419/4885GNAI1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.